Application and Effect
Sitagliptin Phosphate is a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.Sitagliptin phosphate is dipeptidyl peptidase Ⅳ(DDP-4) inhibitor class of drugs developed by the German Merck company and firstly obtained the US Food and Drug Administration approval for the treatment of type 2 diabetes, is a new antidiabetic drug, can improve the body's own ability to reduce high blood glucose levels, and the relatively increase naturally occurring incretin by inhibiting the activity of this enzyme, including the levels of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide, thereby triggering the pancreas to improve insulin production and stop glucose production in liver, and ultimately reduce the clinical effect of blood glucose concentration.Product Sample
Product Packing:
Additional Information:
| Composition | C16H15F6N5O.H3PO4 |
| Assay | 99% |
| Appearance | White to Off-White powder |
| CAS No. | 654671-78-0 |
| Packing | 25KG |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |